Chagin Andrei S, Karimian Elham, Zaman Farasat, Takigawa Masaharu, Chrysis Dionisios, Sävendahl Lars
Pediatric Endocrinology Unit, Department of Woman and Child Health, Karolinska Institutet, Stockholm, Sweden.
Bone. 2007 May;40(5):1415-24. doi: 10.1016/j.bone.2006.12.066. Epub 2007 Jan 9.
Estrogen affects skeletal growth and promotes growth plate fusion in humans. High doses of estrogen have been used to limit growth in girls with predicted extreme tall stature; a treatment which has been associated with severe side effects. Selective estrogen receptor modulators (SERMs) could potentially be used as an alternative treatment. We chose to study the effects of Tamoxifen (Tam), a first generation SERM that has been used in the treatment of pubertal gynecomastia or McCune-Albright syndrome. Cultured fetal rat metatarsal bones were used to study the effects of Tam on longitudinal bone growth. In sectioned bones, chondrocyte apoptosis and proliferation were analyzed by TUNEL assay and BrdU incorporation, respectively. We also used a human chondrocytic cell line, HSC-2/8, to study the effects of Tam on apoptosis (FACS analysis and Cell Death detection ELISA) and caspase activation (caspase substrate cleavage and Western immunoblotting). Tam caused a dose-dependent growth retardation of cultured metatarsal bones. No catch-up growth was observed after Tam was removed from the culture medium. Detailed analysis of sectioned growth plate cartilage revealed increased apoptosis of chondrocytes within the resting and hypertrophic zones. HCS-2/8 cells also underwent apoptosis upon Tam treatment. Tam-induced apoptosis was caspase-dependent and completely abrogated by either caspase-8 or -9 inhibitors. A substrate assay revealed that caspase-8 is first activated followed by caspase-9 and -3. Finally, FasL secretion was stimulated by Tam and blocking of either FasL or Fas decreased Tam-induced apoptosis in chondrocytes. We here describe a novel mechanism of tamoxifen-induced apoptosis in chondrocytes, involving the activation of caspases and the FasL/Fas pathway, which diminishes the potential for bone growth.
雌激素影响人类骨骼生长并促进生长板融合。高剂量雌激素已被用于限制预计身材极高的女孩的生长;这种治疗方法伴有严重副作用。选择性雌激素受体调节剂(SERM)可能可作为一种替代治疗方法。我们选择研究他莫昔芬(Tam)的作用,他莫昔芬是第一代SERM,已用于治疗青春期男性乳腺增生或麦库恩-奥尔布赖特综合征。使用培养的胎鼠跖骨研究Tam对纵向骨生长的影响。在切片骨中,分别通过TUNEL测定法和BrdU掺入法分析软骨细胞凋亡和增殖情况。我们还使用人软骨细胞系HSC-2/8研究Tam对凋亡(流式细胞术分析和细胞死亡检测ELISA)和半胱天冬酶激活(半胱天冬酶底物切割和蛋白质免疫印迹法)的影响。Tam导致培养的跖骨出现剂量依赖性生长迟缓。从培养基中去除Tam后未观察到追赶生长。对切片生长板软骨的详细分析显示,静止区和肥大区内的软骨细胞凋亡增加。HCS-2/8细胞在Tam处理后也发生凋亡。Tam诱导的凋亡是半胱天冬酶依赖性的,并且被半胱天冬酶-8或-9抑制剂完全消除。底物测定显示,半胱天冬酶-8首先被激活,随后是半胱天冬酶-9和-3。最后,Tam刺激FasL分泌,阻断FasL或Fas均可减少Tam诱导的软骨细胞凋亡。我们在此描述了他莫昔芬诱导软骨细胞凋亡的一种新机制,涉及半胱天冬酶的激活和FasL/Fas途径,这降低了骨骼生长的潜力。